Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

Editorial Checklist Reviewed
Affymax, IncJun 22 2010NewsGuard 100/100 Score

Affymax, Inc. (Nasdaq:AFFY) today announced that it has received $30 million in development milestone payments from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. The payments were triggered by the achievement of database lock in the PEARL and EMERALD Phase 3 clinical trials, which evaluated Hematide to treat anemia in chronic renal failure patients.

Affymax and Takeda are collaborating on the development of Hematide and will co-commercialize the product in the United States upon approval. Takeda holds an exclusive license to develop and commercialize Hematide outside the United States, including Japan.

Source:

Affymax, Inc

Posted in: Drug Trial News | Medical Condition News

Tags: , , , ,

Comments (0)

Suggested Reading

Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches
Ozempic effective for patients with chronic kidney damage
A novel approach to photosynthetic production of high-value compounds
Irregular sleep and poor REM sleep linked to higher risk of chronic diseases
AI reveals genetic links in aging, chronic diseases, and lifestyle factors across nine organ systems
Avadel Pharmaceuticals announces publication of RESTORE data highlighting challenges with twice-nightly oxybates and strong patient preference for once-nightly LUMRYZ™ dosing (sodium oxybate) extended-release oral suspension (CIII)
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients
How gut microbiome and fiber diversity shape chronic disease outcomes

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Reducing processed meat consumption could reduce burden of chronic diseases in the USA, study suggests